https://www.zorginstituutnederland.nl/documenten/2008/11/24/alemtuzumab-mabcampath-bij-chronische-lymfatische-leukemie
Alemtuzumab (Mabcampath) bij chronische lymfatische leukemie | Zorginstituut Nederland
alemtuzumabbijleukemienederland
https://profiles.biocentury.com/products/lemtrada_campath-1h_alemtuzumab_(campath_mabcampath_ldp-03_mabcampath-1h_alemtuzumab)
Lemtrada, Campath-1H, alemtuzumab (campath, mabcampath, LDP-03, MabCampath-1H alemtuzumab) -...
Lemtrada, Campath-1H, alemtuzumab (campath, mabcampath, LDP-03, MabCampath-1H alemtuzumab) - BioCentury Product Profiles for the biopharma industry
lemtradacampathalemtuzumabldp
https://adisinsight.springer.com/drugsafety/803851100?error=cookies_not_supported&code=c84a9a3b-5cdf-4a36-a405-f9574e7c146a
Alemtuzumab/Thiamazole - AdisInsight
A 33-year-old woman developed Graves disease and Hashimoto's thyroiditis during treatment with alemtuzumab for multiple sclerosis. Additionally, she developed
alemtuzumabadisinsight
https://pure.psu.edu/en/publications/steroid-free-maintenance-immunosuppression-using-alemtuzumab-in-p/
Steroid-free maintenance immunosuppression using alemtuzumab in pediatric kidney transplantation:...
free maintenancesteroidimmunosuppressionusingalemtuzumab
https://www.informazionisuifarmaci.it/Sezione.jsp?idSezione=579
Alemtuzumab - Informazioni sui farmaci
alemtuzumabinformazionisuifarmaci